Expected in 2017. Plus, the latest in the pipeline, including concentrated insulin systems and the Horizon Automated Glucose Control System

Results from the type 2 diabetes group in Dexcom’s DIaMonD trial show A1c and time-in-range benefits

Training to be tested in a small group before the full launch starts in June

What does donated diabetes data tell us about time-in-range across different age groups?

The diaTribe Foundation’s first “Musings After Hours” discussion with leading experts on digital health and tech in diabetes

One Drop Premium and Bluetooth-enabled Chrome meter available in US and EU, as well as 24/7 in-app support

Launch by end of 2017 in major pharmacies at lower price than other CGMs; No fingerstick calibration needed, 10-day wear, 12-hour warmup

People with type 1 or type 2 diabetes on intensive insulin therapy can qualify. A major win for the diabetes community following years of patient advocacy!

With Roche’s support, mySugr will expand to more countries and will even begin offering a new package with unlimited test strips and diabetes coaching through German...

Continuously delivers GLP-1 agonist for 3-6 months; FDA decision is expected by the end of 2017

New Dexcom and Fitbit collaboration to put CGM data on the wrist, a convenience win and the third smartwatch platform for Fitbit. What else might they develop?

Sanofi’s My Dose Coach app joins other insulin dosing apps recently cleared by the FDA, and new dosing tools from Novo Nordisk/Glooko and others are also in the works

New apps and software updates from mySugr, Insulia, One Drop, as well as food and weight loss apps

Bigfoot Biomedical and Abbott partner to use “next-generation” FreeStyle Libre glucose monitoring sensor (no fingersticks needed) with Bigfoot’s automated insulin...

CGMs with an insulin-dosing claim, like Dexcom’s G5, finally have a path to Medicare reimbursement; possible coverage in 2018 or earlier

Lilly’s Humalog Junior KwikPen offers 0.5 unit dose increments in prefilled, disposable device – a win for highly insulin sensitive users

Comparing Medtronic’s MiniMed 670G to injections and pumps in people with type 1 diabetes, with and without CGM; enrollment to open in May at some trial locations

By Maeve Serino and Adam Brown Learn about what’s new and what’s coming soon in Smart Pens, automated insulin delivery, pumps, and more Diabetes technology moves fast,...

Sanofi’s insulin adjustment app to help people with type 2 diabetes optimize once-daily long-acting basal insulin is now available for Apple and Android devices

The FDA decision on Novo Nordisk’s basal insulin is based on positive safety and efficacy data of Tresiba versus other basal insulins